The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy

Aniruddha Agarwal; Sally A. Ingham; Keegan A. Harkins; DIana V. Do; Quan Dong Nguyen

doi:10.2217/pgs.15.173

The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy

Aniruddha Agarwal, Sally A. Ingham, Keegan A. Harkins, DIana V. Do, Quan Dong Nguyen

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.

Original language	English (US)
Pages (from-to)	309-320
Number of pages	12
Journal	Pharmacogenomics
Volume	17
Issue number	3
DOIs	https://doi.org/10.2217/pgs.15.173
State	Published - Feb 2016

Keywords

HLA
VEGF mutation
diabetic retinopathy
gene therapy
genomic markers
linkage
mutation
pharmacogenomics
polymorphism
viral vectors

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs.15.173

Cite this

@article{de793ce8b11f418c81f396e103086fa5,

title = "The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy",

abstract = "Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.",

keywords = "HLA, VEGF mutation, diabetic retinopathy, gene therapy, genomic markers, linkage, mutation, pharmacogenomics, polymorphism, viral vectors",

author = "Aniruddha Agarwal and Ingham, {Sally A.} and Harkins, {Keegan A.} and Do, {DIana V.} and Nguyen, {Quan Dong}",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = feb,

doi = "10.2217/pgs.15.173",

language = "English (US)",

volume = "17",

pages = "309--320",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy

AU - Agarwal, Aniruddha

AU - Ingham, Sally A.

AU - Harkins, Keegan A.

AU - Do, DIana V.

AU - Nguyen, Quan Dong

PY - 2016/2

Y1 - 2016/2

N2 - Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.

AB - Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.

KW - HLA

KW - VEGF mutation

KW - diabetic retinopathy

KW - gene therapy

KW - genomic markers

KW - linkage

KW - mutation

KW - pharmacogenomics

KW - polymorphism

KW - viral vectors

UR - http://www.scopus.com/inward/record.url?scp=84956630737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956630737&partnerID=8YFLogxK

U2 - 10.2217/pgs.15.173

DO - 10.2217/pgs.15.173

M3 - Review article

C2 - 26807609

AN - SCOPUS:84956630737

SN - 1462-2416

VL - 17

SP - 309

EP - 320

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 3

ER -

The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this